Asia-Pacific Medication-Assisted Treatment (MAT) Market, By Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and Extended Release), Route of Administration (Oral, Parenteral and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals, Specialty Centres, Homecare and Others) Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy and Others), Industry Trends and Forecast to 2029
Market Analysis and Insights
The Food and Drug Administration (FDA) approved three clinical drugs: buprenorphine, methadone, and naltrexone. Medication-assisted treatment (MAT) is applied to cure alcohol use disorder, opioid dependency medication, and opioid overdose prevention medication. Alcohol use disorder (AUD) is a medical condition characterized by an impaired ability to stop alcohol use despite adverse social, occupational, or health consequences. Acamprosate, disulfiram, and naltrexone are the most common medications used to treat alcohol use disorder (AUD). The opioid dependency medication, rise in addiction for opioids among patients. Buprenorphine, methadone, and naltrexone are used to treat opioid use disorders to short-acting opioids such as heroin, morphine, and codeine, as well as semi-synthetic opioids like oxycodone and hydrocodone. These MAT medications are safe for months, years, or even a lifetime.
Market Definition
Medication-assisted treatment (MAT) involves using medications, combined with counseling and behavioral therapies, to provide a complete patient approach for the treatment of substance use disorders. MAT is primarily used to treat addiction to opioids such as heroin and prescription pain relievers. The aim of MAT is proper recovery, which includes improved patient survival, increased treatment retention, reduced illicit response, and a rise in pregnancy outcomes among women. For opioid overdose prevention medication, naloxone is used to prevent opioid overdose by reversing the toxic effects of the overdose. According to the World Health Organization (WHO) and Substance Abuse and Mental Health Services Administration (SAMHSA) naloxone is one of many medications considered essential to a functioning health care system.
The Asia-Pacific medication-assisted treatment is supportive and aims to reduce the severity of the symptoms. Data Bridge Market Research analyses that the medication-assisted treatment (MAT) market will grow at a CAGR of 10.5% from 2022 to 2029.
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Million, Pricing in USD |
|
Segments Covered |
By Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and Extended Release), Route of Administration (Oral, Parenteral and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals, Specialty Centres, Homecare and Others) Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy and Others) |
|
Countries Covered |
China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific. |
|
Market Players Covered |
Indivior PLC, Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Pfizer Inc., Glenmark Pharmaceutical Inc., Viatris Inc., Alvogen, Accord Healthcare, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd.Amneal Pharmaceuticals LLC. among others |
Asia-Pacific Medication-Assisted Treatment (MAT) Market Dynamics
Drivers
- The Rise In The Incidence Of Opioid Use Disorders (Opioid Dependency Medication)
Medication-assisted treatment (MAT) is using medications in combination with counseling and behavioral therapies to provide a "whole-patient" approach to treating substance use disorders. Medications used in MAT are approved by the Food and Drug Administration (FDA), and MAT programs are clinically driven and tailored to meet each patient's needs.
For instance,
- The prevalence of high-risk opioid use (by injection or long duration/regular use) among adults (aged 15–64) in Asia-Pacific has been relatively stable for many years, with estimates of users standing at around 0.35 % of the EU population
As the companies are constantly engaged in research and developmental activities, the knowledge about the incidence of alcohol use disorder and opioid use disorders would help find novel solutions and aid in more collaborations. This signifies the increase in research and development-related investments for initiating generic medications in medication-assisted treatment (MAT), which is expected to boost the market growth.
- The Funding By The Government For Medication-Assisted Treatment (MAT)
Despite the established effectiveness of pharmacotherapies for treating opioid use and alcohol disorders, limitations to implementing medications for addiction treatment (MAT) by specialty treatment programs have been observed. Particular attention needs to be paid to specific sources for funding, organizational structure, and workforce resources, making a long-term investment that aligns the payment with the potential future beneficiaries.
For instance,
- In February 2021, the Integrated Substance Use Disorder Training Program (ISTP) was funded to plan, develop, and operate a 12-month full-time or 24-month half-time training program for nurse practitioners and physician assistants for medication-assisted treatment (MAT). The funding expands the workforce trained to provide care for individuals in need of mental health and opioid use disorder prevention
The funding by the government would result in the patient's safety and cost savings. In addition, hospitals and healthcare agencies would administer this treatment at a lower price through collaboration with government organizations. Hence the advancements in research and development activities and funding by the government are expected to drive the market growth.
Opportunities
- Rise In Healthcare Expenditure
Moreover, the rise in the research and development activities and increasing investments by government and private organizations will boost new opportunities for the market's growth rate.
For instance,
- In March 2020, the data by the National Institute of Health (NIH) state that Medicare spent around USD 829,500 million in 2020, or 20 percent of the total NHE
Growing healthcare expenditure is also beneficial for further economic development and growth of the healthcare sector. In addition, the increase in disposable income of the population is a favorable factor. The above are expected to create lucrative medication-assisted treatment (MAT) opportunities.
- Strategic Initiative By Market Players
The demand for medication-assisted treatment (MAT) has increased in the U.S. and Asia-Pacific due to the timely treatment of chronic conditions. These favourable factors enhance the need for medications, and to achieve the market demand, minor and major market players are utilizing various strategies.
The major players are also trying to devise specific strategies, such as product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth running of the business, avoid risks, and increase the long-term growth in the sales of the market.
For instance,
- In April 2021, Adamis Pharmaceuticals Corporation with USWM announced the launch and availability of a high-dose ZIMHI injectable naloxone product to help combat opioid overdose deaths. The launch is expected to increase the product segment revenue, which will boost the market growth, and ZIMHI being made available at a discounted rate for first responders and community health organizations
These strategic initiatives by the market players, including acquisition, conferences, and focused segment product launches, are helping the companies grow and improve the company's product portfolios, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players provide an opportunity that is helping them to drive market growth.
Restraint/Challenge
- Side Effects Of Drugs Used In Medication-Assisted Treatment (MAT)
Medication-assisted treatment (MAT) involves the use of medications, collated with counselling and behavioural therapies, to provide a "whole-patient" approach as part of the comprehensive treatment strategy. Therefore, the present high cost is expected to show a descending trend in the future. MAT has been shown to be most effective for treating alcohol and opioid use disorders. However, certain side effects have been reported
For instance,
- Methadone and buprenorphine, the generic medications are chemically similar to opioids, so their side effects can be similar too. These may include constipation, drowsiness, and dizziness. Some people may experience more severe side effects
The adverse complications reported would lead to a decline in sales of the medicated opioid dependency medications, which would limit the sales of the medicines. In addition, it would affect the reliability of manufacturers involved in this market and hence expected to restrain the market growth.
COVID-19 Impact on the Medication-Assisted Treatment (MAT) Market
During the pandemic, medication-assisted treatment (MAT) remarkably reduces mortality and morbidity of patients with COVID-19. Further large-scale studies are needed to approve these results. A protocol for medication-assisted treatment (MAT) in COVID-19 infection should be defined to achieve the best possible clinical outcomes. Clinical trials were conducted during COVID-19 medication for opioid use disorder (MOUD) services are vital in addressing the opioid crisis, and COVID-19 has significantly impacted MOUD delivery.
Recent Development
- In April 2021, Adamis Pharmaceuticals Corporation with USWM announced the launch and availability of a high-dose ZIMHI injectable naloxone product to help combat opioid overdose deaths. The launch is expected to increase the product segment revenue, which will boost the market growth, and ZIMHI being made available at a discounted rate for first responders and community health organizations
Asia-Pacific Medication-Assisted Treatment (MAT) Market Scope
The medication-assisted treatment (MAT) market is segmented on the basis of eight segments: type, products, drug type, dosage form, route of administration, population type, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Medication
- Therapy
On the basis of type the Asia-Pacific medication-assisted treatment (MAT) market is segmented into medication and therapy.
Products
- Buprenorphine and Naloxone
- Naltrexone
- Buprenorphine
- Methadone
- Naloxone
- Disulfiram
- Acamprosate
On the basis of products, the Asia-Pacific medication-assisted treatment (MAT) market is segmented into buprenorphine and naloxone, naltrexone, buprenorphine, methadone, naloxone, disulfiram and acamprosate.
Drug Type
- Generics
- Branded
On the basis of drug type, the Asia-Pacific medication-assisted treatment (MAT) market is segmented into generics and branded.
Dosage Form
- Immediate Release
- Extended Release
On the basis of dosage form, the Asia-Pacific medication-assisted treatment (MAT) market is segmented into immediate release and extended release.
Route of Administration
- Oral
- Parenteral
- Others
On the basis of route of administration, the Asia-Pacific medication-assisted treatment (MAT) market is segmented into oral, parenteral and others.
Population Type
- Adults
- Teenage
On the basis of population type, the Asia-Pacific medication-assisted treatment (MAT) market is segmented into adults and teenage.
End User
- Rehabilitation Clinics
- Hospitals
- Specialty Centers
- Homecare
- Others
On the basis of end user, the Asia-Pacific medication-assisted treatment (MAT) market is segmented into rehabilitation clinics, hospitals, specialty centers, homecare and others.
Distribution Channel
- Hospital Pharmacy
- Direct Tender
- Retail Pharmacy
- Online Pharmacy
- Others
On the basis of distribution channel, the Asia-Pacific medication-assisted treatment (MAT) market is segmented into hospital pharmacy, direct tender, retail pharmacy, online pharmacy and others.
Medication-Assisted Treatment (MAT) Market Regional Analysis/Insights
The Asia-Pacific medication-assisted treatment (MAT) market is analysed and market size insights and trends are provided by regions, product type, type, application, workflow, end user and distribution channel ass referenced above.
The countries covered in the medication-assisted treatment (MAT) market report are China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and the Rest of Asia-Pacific.
China is expected to dominate the market due to the rise in cases of alcohol disorders and the rise in the population receiving medication-assisted treatment (MAT) and medication-assisted awareness programs medication-assisted treatment (MAT) in Asia-Pacific region.
The country section of the report also provides individual market impacting factors and domestic regulation changes that impact the current and future market trends. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the significant pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Medication-Assisted Treatment (MAT) Market Share Analysis
The Asia-Pacific medication-assisted treatment (MAT) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, the Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the medication-assisted treatment market.
Some of the major players operating in the medication-assisted treatment (MAT) market are Indivior PLC, Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Pfizer Inc., Glenmark Pharmaceutical Inc., Viatris Inc., Alvogen, Accord Healthcare, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC. among others.
SKU-
